China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…
Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…
China A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator the National Medical Products Administration (NMPA) approved a total of 11 new drugs, 6 imported and 5 domestic Made with Visme…
China Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we…
See our Cookie Privacy Policy Here